stay tuned:
elixi news from the
world

Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation

Vitrakvi (larotrectinib), first ‘histology-independent’ treatment for solid tumours with a specific gene mutation

EMA’s human medicines committee has recommended granting a marketing authorisation in the European Union for Vitrakvi (larotrectinib) for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. Treatment with Vitrakvi is recommended for patients whose disease has spread or cannot be surgically removed, and who have no other satisfactory treatment options.

Vitrakvi is the first so-called ‘histology-independent’ cancer treatment recommended for approval in the EU. This means that it can be used to treat non-haematological (i.e. that do not begin in the blood or bone marrow) tumours with this specific mutation, regardless of where in the body the tumour originated. Before patients can be started on the medicine, the presence of the mutation in the tumour should be confirmed by a validated test.

The active substance in Vitrakvi – larotrectinib – targets a very specific genomic alteration of a patient’s tumour. This occurs when NTRK genes that encode specific proteins are abnormally fused to a gene. This mutation, called NTRK gene fusion, leads to the development of proteins that can cause cancer cells to grow. Vitrakvi blocks the action of these proteins and in doing so inhibits the growth of the cancer.

NTRK gene fusions can be observed very frequently in a certain number of rare cancer types that affect both adults and children. In addition, this gene fusion occurs rarely in some of the most common cancer types.

The efficacy and safety of Vitrakvi were studied in three single-arm trials (i.e. studies with no control group) that included a total of 102 adults and children with cancer that were evaluated. These patients had either already received standard therapy, or would have had to undergo disfiguring surgery, or were unlikely to respond to available therapies.

The share of patients who responded to treatment with Vitrakvi was 67%. Of those, the response lasted six months or longer in 88% and 12 months or longer in 75%. Tumour responses were seen both in rare tumour types such as infantile fibrosarcoma and salivary gland tumours, as well as in common diseases such as lung and colon cancer.

The most common side effects were tiredness, increased levels of liver enzymes, dizziness, constipation, nausea, anaemia (low red blood cell count), and vomiting.
The CHMP recommended a conditional approval for this medicine. This is one of the EU’s regulatory mechanisms to facilitate early access to medicines that fulfil an unmet medical need. This type of approval allows the Agency to recommend a medicine for marketing authorisation with less complete data than normally expected, in cases where the benefit of a medicine’s immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Share this article

Tweet
Share
Pin it
Share

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter

    Headquarter

    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)

    Switzerland

    Tel.  +41 (0)91 6822040
    info@elixi-int.com

    Subsidiary

    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)

    Italy

    Tel.  +41 (0)91 6822040
    europe@elixi-int.com

    Subsidiary

    Elixi Pharma pte. ltd.
    16 Raffles quay #33-03
    Hong Leong building

    Singapore

    Tel.  +41 (0)91 6822040
    singapore@elixi-int.com

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy